Trade Summary

2 days ago, Schneyer Mark C., serving as EVP, CFO at Acadia Pharmaceuticals Inc (ACAD), sold 3,506 shares at $21.79 per share, for a total transaction value of $76,396.00. Following this transaction, Schneyer Mark C. now holds 66,145 shares of ACAD.

This sale represents a 5.00% decrease in Schneyer Mark C.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, May 4, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 5, 2026, 1 day after the trade was made.

Acadia Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.